Oct31
Medicare sees increase in observation payments[This quarterly column on coding in the ED is written byCaral Edelberg, CPC, CCS-P, CHC, president of Edelberg Compliance Associates, Baton Rouge, LA. If there are coding issues you would like to see addressed in this column, contact Edelberg at phone: (225) 454-0154. EFAX: (225) 612-6904. E-mail:caral@cedelbergcompliance.com.]Steady growth in Medicare [...]
Oct31
2009 NOV 1 – (NewsRx.com) Upon the recent FDA approval of pralatrexate (Folotyn?, Allos Therapeutics, Inc.) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), the National Comprehensive Cancer Network (NCCN) has updated the NCCN Clinical Practice Guidelines in Oncology? for Non-Hodgkin’s Lymphomas to include pralatrexate as a suggested treatment regimen (see [...]
Oct31
2009 NOV 1 – (NewsRx.com) Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt? (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia. Novartis plans to launch Fanapt in the US in [...]
Oct31
2009 NOV 1 – (NewsRx.com) Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has taken the initial steps to obtain the CE Mark for its Food and Drug Administration (FDA) approved MammoView? line of surgical endoscopy instruments. This will allow the MammoView? line to be sold throughout the European [...]
Oct31
2009 NOV 1 – (NewsRx.com) ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company’s proprietary Glycosylation Independent Lysosomal Targeting technology, announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical [...]
Oct31
2009 NOV 1 – (NewsRx.com) A one day session on the use of adaptive designs for more efficient conduct of clinical trials for CNS indications chaired by Andrew C. Leon, PhD, Cornell University, and Donald Berry, PhD, M. D. Anderson, Department of Biostatistics, was held 5 October 2009, at the International Society for CNS [...]
Oct31
2009 NOV 1 – (NewsRx.com) Based on its annual assessment of companies making innovative contributions in healthcare, Frost & Sullivan recognizes Agile Therapeutics, Inc. (Agile) with the 2009 North American Pharmaceuticals & Biotechnology Healthcare Innovation of the Year Award for its outstanding achievements in drug development. Agile’s lead product, AG200-15 with SKINFUSION?, offers great [...]
Oct31
EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer’s Disease Patient2009 NOV 1 – (NewsRx.com) The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer’s [...]
Oct31
2009 NOV 1 – (NewsRx.com) AstraZeneca (NYSE: AZN) announced the U.S. Food and Drug Administration (FDA) approved CRESTOR=AE (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and [...]
Oct31
2009 NOV 1 – (NewsRx.com) Solvay Pharmaceuticals, Inc. announced that new data confirm that CREON (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). EPI is a condition resulting from a deficiency in the production and/or [...]